DiscoverMarkets & Money Today | 2 Min News | The Daily News Now!VistaGen stock rises after completing Phase 3 trial for anxiety drug By Investing.com
VistaGen stock rises after completing Phase 3 trial for anxiety drug By Investing.com

VistaGen stock rises after completing Phase 3 trial for anxiety drug By Investing.com

Update: 2025-11-03
Share

Description

VistaGen Therapeutics makes significant progress in developing a new anxiety treatment, fasedienol, which showed promising results in a Phase Three clinical trial. This intranasal medicine could offer a faster, more targeted solution for social anxiety, potentially becoming the first on-the-spot treatment approved by the FDA. With positive results expected soon, millions of Americans living with social anxiety are watching closely for this potential breakthrough.

The Daily News Now! — Every city. Every story. AI-powered.


Hosted on Acast. See acast.com/privacy for more information.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

VistaGen stock rises after completing Phase 3 trial for anxiety drug By Investing.com

VistaGen stock rises after completing Phase 3 trial for anxiety drug By Investing.com